Syngr2 promotes viral replication by facilitating the formation of viral replication factories. Key findings include:
SFTSV Interaction: Syngr2 interacts with the nonstructural protein NSs of Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV), enabling reconstruction of lipid droplets into inclusion bodies (IBs) for viral RNA replication. Silencing Syngr2 reduces IB size and viral titers by >50% .
PCV2 Replication: In Porcine Circovirus 2 (PCV2), Syngr2 knockdown via CRISPR-Cas9 or siRNA reduces viral replication by 75%–90%, with delayed replication kinetics observed within 24 hours post-infection .
Overexpression Impact: Ectopic Syngr2 expression in HeLa cells increases SFTSV titers by 3–5-fold and PCV2 replication efficiency .
Mechanistic Insight: Syngr2’s first intraluminal loop (residues 60–63 in pigs/63–66 in rats) is critical for vesicle membrane integration. The SYNGR2 p.Arg63Cys variant disrupts this domain, reducing PCV2 replication efficiency .
Recombinant Syngr2 is utilized in:
Viral Pathogenesis Studies: Investigating host-pathogen interactions for RNA viruses (e.g., SFTSV) and DNA viruses (e.g., PCV2) .
Protein-Protein Interaction Assays: Mapping binding domains using pull-down assays and co-immunoprecipitation .
Structural Biology: Analyzing membrane topology via mutagenesis and fluorescence tagging .
Syngr2 is evolutionarily conserved across mammals. The SYNGR2 p.Arg63Cys variant in pigs reduces PCV2 replication, suggesting adaptive host-pathogen dynamics. Structural homology with human SYNGR2 (84% identity) enables translational studies in viral entry mechanisms .